Last reviewed · How we verify
NCT06863090
In Vivo Dosimetry for Brachytherapy Study
trial in Prostate Cancer in 20 participants. Currently enrolling.
1 March 2026
Quick facts
| Lead sponsor | East and North Hertfordshire NHS Trust |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 3 March 2025 |
| Primary completion | 1 March 2026 |
| Estimated completion | 1 March 2026 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Gynaecological Cancer — all drugs for Gynaecological Cancer →
Sponsor
East and North Hertfordshire NHS Trust
Who can join
18 and older, any sex, with Prostate Cancer or Gynaecological Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main study aim is the investigate the clinical use of in vivo dosimeters (small measurement devices) for brachytherapy (internal radiotherapy).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06863090
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other East and North Hertfordshire NHS Trust trials
Trials by the same sponsor.
- NCT07069998 — AI-guided AF Treatment · NA · not yet recruiting
- NCT06915909 — Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial · NA · not yet recruiting
- NCT06623123 — Oto Smartphone App in Treating Tinnitus Amongst Adult Patients Compared with Standard Talking Therapies · Phase 3 · recruiting
- NCT06400927 — Safety of AI-Powered Virtual Assistant in Outpatient Management of Heart Failure · NA · recruiting
- NCT06124612 — An Investigator-initiated Linked Study to OCEANIC-AF · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06863090 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by East and North Hertfordshire NHS Trust
- Last refreshed: 11 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06863090.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing